Related Experiment Video
Updated: Jul 2, 2026
Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
Transcriptomic-based molecular classification of ampullary adenocarcinoma
Xumin Huang1, Weikang Hu2, Yang Wu1
1Pancreas Center, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China; Pancreas Institute, Nanjing Medical University, Nanjing, 210000, China; Jiangsu Provincial Key Laboratory of Chronic Digestive Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210000, China.
Ampullary adenocarcinoma (AMPAC) classification is improved by a new transcriptomic-based system (AMS). This system identifies two subtypes, AMS-M and AMS-C, with distinct molecular features and prognostic implications, guiding personalized therapy.
Area of Science:
- Oncology
- Genomics
- Translational Research
Background:
- Ampullary adenocarcinoma (AMPAC) is a rare cancer with highly variable outcomes.
- Current classification methods lack prognostic accuracy and fail to capture molecular heterogeneity.
Purpose of the Study:
- To develop a molecular classification for AMPAC using transcriptomic data.
- To understand the molecular drivers of AMPAC heterogeneity and identify therapeutic targets.
Main Methods:
- Integrated bulk and single-cell RNA sequencing (scRNA-seq) with clinicopathological data.
- Developed a transcriptomic-based molecular subtyping system (AMS) for AMPAC.
- Investigated the role of MUC16 in AMPAC progression and chemosensitivity.
Main Results:
- Introduced the AMS classification with two subtypes: AMS-M (mesenchymal, unfavorable prognosis) and AMS-C (classical, better prognosis).
- AMS-M tumors show increased epithelial-mesenchymal transition (EMT) and stromal activation.
- MUC16 was identified as a key biomarker overexpressed in AMS-M, and its knockout reversed EMT and improved chemosensitivity.
Conclusions:
- The AMS classification provides prognostic and therapeutic insights for AMPAC.
- Tumor microenvironment plays a critical role in AMPAC heterogeneity.
- MUC16 is a potential therapeutic target for precision oncology in AMPAC.